How far away from having an effective treatment option for progressive multiple sclerosis are we?

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

(2017) Daniel Ontaneda et al.   LANCET

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

(2016) Afsaneh Shirani et al.   Neurotherapeutics

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

(2015) Daniel Ontaneda et al.   LANCET NEUROLOGY

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY